Filip J. Baert

Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

Filip J. Baert, Geert D’Haens, Marc Peeters et al. · Gastroenterology · 1999 · 467 citations · Full text

Life Sciences, Immunology, Pathology +12

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Ryan C. Ungaro, Clara Yzet, Peter Bossuyt et al. · Gastroenterology · 2020 · 238 citations · Full text

Veterinary Medicine, Clinical Sciences, Immunology +13

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Martine De Vos, Édouard Louis, Jørgen Jahnsen et al. · Inflammatory Bowel Diseases · 2013 · 204 citations

Medicine, Clinical Sciences, Internal Medicine +14

Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method

Liselotte Coorevits, Filip J. Baert, Hilde Vanpoucke · Clinical Chemistry and Laboratory Medicine (CCLM) · 2012 · 67 citations

Medicine, Internal Medicine, Pathology +16

Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn’s Disease

Daniël R. Hoekman, Judith A. Stibbe, Filip J. Baert et al. · Journal of Crohn s and Colitis · 2018 · 52 citations · Full text

Medicine, Clinical Sciences, Surgery +14